{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/SLN",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Silence Therapeutics plc (NASDAQ: SLN) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nSilence Therapeutics plc is listed on NASDAQ under ticker SLN. Its ISIN is US82686Q1013 and its LEI is 213800SSURRJBX85SQ91. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United Kingdom. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 51 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 6.5 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-11-05 and is of type regulatory_filing, 3 days before the record date. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days. The NASDAQ median filing count is 52 and the sector median filing count is 63.0.\n\n## Auditor\n\nThe auditor of record is PricewaterhouseCoopers LLP, located in Reading, United Kingdom. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 7 research houses: Chardan, Cantor, Goldman Sachs, H.C. Wainwright & Co., LLC, Jefferies LLC, Morgan Stanley and William Blair.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed filings for the issuer in the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n10 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001479615.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/SLN (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/SLN (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm",
    "state": "sourced",
    "value": "PricewaterhouseCoopers LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm",
    "state": "sourced",
    "value": "876"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm",
    "state": "sourced",
    "value": "Reading, United Kingdom"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/SLN",
  "coverage": {
   "count": 7,
   "houses": [
    {
     "analyst": "Keay Nakae, CFA",
     "house": "Chardan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Prakhar Agrawal",
     "house": "Cantor",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Richard Law, Ph.D.",
     "house": "Goldman Sachs",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Patrick R. Trucchio, CFA",
     "house": "H.C. Wainwright & Co., LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Andrew Tsai",
     "house": "Jefferies LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Michael E Ulz",
     "house": "Morgan Stanley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Myles R. Minter, PhD",
     "house": "William Blair",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx",
     "result": "read: 7 of 14 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 4,
    "corporate_news": 6,
    "director_change": 4,
    "directors_dealings": 11,
    "prospectus": 5,
    "regulatory_filing": 15,
    "results": 6
   },
   "cadence_median_gap_days": 6.5,
   "filing_days": 27,
   "filings": 51,
   "latency_days": 3,
   "latest": [
    {
     "category": "SCHEDULE 13G",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1479615/000031506626002833/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    },
    {
     "category": "DEFA14A",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526425238/d189864ddefa14a.htm",
     "title": "DEFA14A — DEFA14A",
     "type": "agm_egm"
    },
    {
     "category": "DEFA14A",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526424702/d172259ddefa14a.htm",
     "title": "DEFA14A — DEFA14A",
     "type": "agm_egm"
    },
    {
     "category": "8-K",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526424695/d172259d8k.htm",
     "title": "8-K — 8-K (items 1.01,7.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/1479615/000091957426006906/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/SLN",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-09-17",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US82686Q1013"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001479615.json",
    "state": "sourced",
    "value": "United Kingdom"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US82686Q1013)",
    "state": "sourced",
    "value": "213800SSURRJBX85SQ91"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001479615.json",
    "state": "sourced",
    "value": "Silence Therapeutics plc"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001479615.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001479615.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "SLN"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:9caa320064322b898f4c15333b31831e2e0d6ae3803985a2ea26afbfef83403f",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/SLN",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:9caa320064322b898f4c15333b31831e2e0d6ae3803985a2ea26afbfef83403f",
 "path": "/us/NASDAQ/SLN",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "Silence Therapeutics plc is listed on NASDAQ under ticker SLN. Its ISIN is US82686Q1013 and its LEI is 213800SSURRJBX85SQ91. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United Kingdom. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 51 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 6.5 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-11-05 and is of type regulatory_filing, 3 days before the record date. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days. The NASDAQ median filing count is 52 and the sector median filing count is 63.0.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is PricewaterhouseCoopers LLP, located in Reading, United Kingdom. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 7 research houses: Chardan, Cantor, Goldman Sachs, H.C. Wainwright & Co., LLC, Jefferies LLC, Morgan Stanley and William Blair.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed filings for the issuer in the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "10 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001479615.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/SLN"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://silence-therapeutics.com/investors/share-information/analyst-coverage-key-advisers/default.aspx"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/SLN"
  }
 ],
 "title": "Silence Therapeutics plc (SLN) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}